Clinical Trial Update: A Phase Ⅰ/Ⅱa Clinical Study of GEN-725 in Combination With Dositinib [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2a clinical study evaluating GEN-725 in combination with Dositinib is currently recruiting for non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Dositinib
• GEN-725

Snippet

Sponsor: Henan Genuine Biotech Co., Ltd. | Conditions: Non-Small Cell Lung Cancer | Phase 1, Phase 2 | Status: RECRUITING